These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30146822)

  • 1. Clinical Application of Pro-Gastrin-Releasing Peptide.
    Fang L; Huang Z; Lin Y; Fu J; Liang X; Liu F
    Clin Lab; 2018 Jul; 64(7):1259-1268. PubMed ID: 30146822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
    Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
    J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 5. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
    Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
    Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
    Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
    Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reference intervals for plasma pro-gastrin releasing peptide (ProGRP) levels in healthy adults of Chinese Han ethnicity.
    Zhang J; Zhao Y; Chen Y
    Int J Biol Markers; 2014 Dec; 29(4):e436-9. PubMed ID: 24723213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
    Bubanović G; Pavićević R; Franjević A
    Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
    Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
    Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pleural pro-gastrin releasing peptide is a potential diagnostic marker for malignant pleural effusion induced by small-cell lung cancer.
    Wang YF; Yang Q; Hai L; Zhou F; Zhang L; Wang YJ; Gao WH; Yan L; Jiang TW; Huang JH; Chen H; Zhou Q; Porcel JM; Zheng WQ; Hu ZD
    J Thorac Dis; 2024 Jul; 16(7):4440-4446. PubMed ID: 39144330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
    Yang HJ; Gu Y; Chen C; Xu C; Bao YX
    Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
    Ni J; Guo Z; Zhang L
    Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics of patients with nonsmall cell lung carcinoma with elevated serum progastrin-releasing peptide levels.
    Goto K; Kodama T; Hojo F; Kubota K; Kakinuma R; Matsumoto T; Ohmatsu H; Sekine I; Nagai K; Nishiwaki Y
    Cancer; 1998 Mar; 82(6):1056-61. PubMed ID: 9506349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
    Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
    Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.